Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bintrafusp Alfa and Eribulin in Metastatic TNBC
NCT03579472Phase 1Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2018
- Primary completion
- Sep 2022
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of bintrafusp alfa in triple-negative breast cancer (TNBC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Recommended Phase II Dose. Started May 2018; status: terminated.
02
Drugs
bintrafusp alfa
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03579472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03579472.